Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
05/08/2026 13:19
BRIEF-Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020 Aug 5 (Reuters) - Lexeo Therapeutics, Inc. LXEO.O:
LEXEO THERAPEUTICS RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR LX2020 FOR THE TREATMENT OF PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY
LEXEO THERAPEUTICS RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR LX2020 FOR THE TREATMENT OF PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY
LEXEO THERAPEUTICS, - LX2020 HOLDS RMAT, ORPHAN DRUG, AND FAST TRACK DESIGNATIONS FROM FDA
Source text: ID:nGNX1X7gsQ
Further company coverage: LXEO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease